NSPA CEO Hina Waleed exposed alleged exploitation within the Aasandha medical scheme, where private providers inflated drug prices for profit, notably charging MVR 23,000 for a USD 500 injection. She highlighted that some medicines were sold without proper import registration, leading the government to implement price controls and welfare assistance to address the issue. Reforms starting October 1 allow patients to use personal insurance alongside Aasandha, with further improvements planned in the upcoming budget for a more transparent and sustainable system.